Clovis Oncology, Inc. (NASDAQ:CLVS) insider Gillian C. Ivers-Read sold 3,000 shares of the business’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $64.16, for a total value of $192,480.00. Following the completion of the transaction, the insider now directly owns 182,583 shares in the company, valued at $11,714,525.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.
Shares of Clovis Oncology, Inc. (NASDAQ CLVS) traded down $2.90 during trading hours on Thursday, hitting $59.88. The stock had a trading volume of 1,262,648 shares, compared to its average volume of 1,098,555. The company has a debt-to-equity ratio of 0.94, a current ratio of 3.19 and a quick ratio of 3.16. Clovis Oncology, Inc. has a one year low of $45.42 and a one year high of $99.45. The firm has a market capitalization of $2,940.00, a price-to-earnings ratio of -7.23 and a beta of 1.38.
Clovis Oncology (NASDAQ:CLVS) last released its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($1.24) EPS for the quarter, missing analysts’ consensus estimates of ($1.18) by ($0.06). The company had revenue of $16.81 million during the quarter, compared to analysts’ expectations of $21.12 million. Clovis Oncology had a negative net margin of 947.47% and a negative return on equity of 122.06%. During the same period in the previous year, the company posted ($1.70) earnings per share. research analysts anticipate that Clovis Oncology, Inc. will post -7.65 EPS for the current year.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. raised its position in Clovis Oncology by 0.7% in the 2nd quarter. PNC Financial Services Group Inc. now owns 2,820 shares of the biopharmaceutical company’s stock valued at $265,000 after buying an additional 20 shares during the last quarter. Hanseatic Management Services Inc. raised its position in Clovis Oncology by 0.3% in the 2nd quarter. Hanseatic Management Services Inc. now owns 13,693 shares of the biopharmaceutical company’s stock valued at $1,282,000 after buying an additional 37 shares during the last quarter. Aperio Group LLC raised its position in Clovis Oncology by 1.7% in the 2nd quarter. Aperio Group LLC now owns 5,093 shares of the biopharmaceutical company’s stock valued at $477,000 after buying an additional 83 shares during the last quarter. Greenwood Capital Associates LLC raised its position in Clovis Oncology by 4.0% in the 2nd quarter. Greenwood Capital Associates LLC now owns 5,485 shares of the biopharmaceutical company’s stock valued at $514,000 after buying an additional 212 shares during the last quarter. Finally, Amalgamated Bank raised its position in Clovis Oncology by 10.4% in the 2nd quarter. Amalgamated Bank now owns 4,811 shares of the biopharmaceutical company’s stock valued at $450,000 after buying an additional 454 shares during the last quarter.
Clovis Oncology Company Profile
Clovis Oncology, Inc is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company’s product candidates include Rociletinib, Rubraca (Rucaparib) and Lucitanib. Rucaparib is an oral, small molecule poly adenosine diphosphate (ADP)-ribose polymerase (PARP) inhibitor of PARP1, PARP2 and PARP3 approved as a monotherapy for the treatment of patients with deleterious breast cancer (BRCA) (human genes associated with the repair of damaged deoxyribonucleic acid (DNA)) mutation (germline and/or somatic) associated advanced ovarian cancer.
Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.